



Enzymotec Ltd.  
Investor Relations Department  
Sagi 2000 Industrial Park P.O. Box6  
Migdal HaEmeq 23106  
Israel

[Visit IR website](#)   
[Sign-up for email alerts](#) 

**NASDAQ: ENZY <sup>1</sup>**

Last Trade:	11.15
Trade Time:	4:00 PM ET Oct 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	5.20 - 12.35
Volume	N/A
Market Cap. (\$M)	255.335
Shares Out (M)	22.900


<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

We are a leading global supplier of specialty lipid-based products and solutions. We develop, manufacture and market innovative bio-functional lipid ingredients, as well as final products, based on sophisticated proprietary processes and technologies. We deliver our products and solutions through the following two reportable segments:

1. Nutrition segment: This segment develops and manufactures nutritional ingredients for infant formulas and dietary supplements. These ingredients include InFat - which is sold and marketed by Advanced Lipids, our joint venture with AAK, InFat is a proprietary, clinically-proven infant formula fat ingredient that more closely resembles human breast milk fat to facilitate healthy infant development. Other ingredients are premium phospholipid-based bioactive ingredients for nutritional supplements. Our best-selling nutritional ingredient for dietary supplements is krill oil, which provides the benefits of omega-3 fatty acids. Our other nutritional ingredients for dietary supplements are targeted at improving brain health and providing benefits in memory, learning abilities and

## Stock Performance



## Press Releases [\[ View all \]](#)

Aug 30, 2017

[Enzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Springs Healthcare](#)

Aug 28, 2017

[Enzymotec Ltd. Responds to Unsolicited Proposal from Frutarom Ltd.](#)

Aug 16, 2017

[Enzymotec Ltd. Reports Second Quarter 2017 Unaudited Financial Results](#)

Jul 28, 2017

[Enzymotec Ltd. Announces Appointment of Dror Israel as Chief Financial Officer](#)

Jul 26, 2017

[Enzymotec to Report Second Quarter 2017 Financial Results](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

Mar 16, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)

- concentration.
2. VAYA Pharma segment:  
This segment develops, manufactures and sells branded lipid-based medical foods for the dietary management of medical disorders and common diseases. This is a research-based, specialty pharmaceutical segment, which currently offers medical foods products for the cardiovascular and neurological markets. Our VAYA Pharma products are currently the only products sold by us for use by end users.

... [\(more\)](#)